![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/262521-500486304-kiniksa-2c-final-copy-jpg-100x70.jpeg)
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $405 - $415 million – – Abiprubart clinical development fully funded; Phase 2b …